Moffitt Cancer Center's CancerX Accelerator Welcomes Second Cohort of Startups

The CancerX accelerator at Moffitt Cancer Center has announced the selection of its second cohort of startups for 2025. This initiative has identified 14 promising startups that aim to improve cancer care through innovative solutions, continuing the efforts of the InnovationX program launched in 2018.

Focus on Improving Cancer Care

The CancerX Accelerator at Moffitt Cancer Center is designed to support early-stage startups that are working on advancing cancer care. The 14 startups selected for the 2025 cohort will have access to a range of resources, including industry champions and experienced mentors. These startups will receive product feedback and pilot opportunities, which are crucial for their growth and development.

Among the selected startups is Arcascope, which uses circadian clock insights to optimize cancer therapy. By leveraging AI and wearable devices, Arcascope focuses on the timing of cancer therapies to enhance their effectiveness. This approach also involves rescuing failed drugs for patients, providing oncologists with new tools for treatment.

Collaboration and Support

The CancerX Accelerator operates in collaboration with the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH). This partnership provides startups with valuable insights and support, facilitating their growth and integration into the healthcare system.

Accelerators like CancerX have become essential springboards for startup growth, offering support that extends beyond initial bootcamp-style programs. These accelerators have evolved into growth engines, focusing on thematic areas such as healthtech, climate, and artificial intelligence. They are often backed by venture capital firms or universities, providing a robust ecosystem for startups to thrive.

The Path to Success

Participation in an accelerator program requires startups to demonstrate strong founding teams, customer validation, and adaptability. Clarity in communication and long-term thinking are favored, as they support scalable visions. For startups in the CancerX Accelerator, engaging fully in workshops and events, setting clear objectives early on, and building long-term relationships are critical for success.

Maintaining visibility after the program is also essential for sustained growth and success. As accelerators continue to specialize across various verticals and geographies, the importance of customizing applications for specific programs becomes evident. Strong applications require clarity and evidence, ensuring that startups align with the accelerator's objectives and goals.

Looking Ahead

The CancerX Accelerator is poised to continue its impact on cancer care, with applications for the 2026 cohort opening to the public on September 9, 2025. As hundreds of accelerator programs operate worldwide in 2025, the CancerX Accelerator stands out for its focus on improving cancer care through innovation and collaboration.

By fostering an environment that encourages adaptability, leadership potential, and customer validation, the CancerX Accelerator is well-positioned to drive meaningful advancements in the fight against cancer. As the selected startups embark on their journey, the program's emphasis on clarity, evidence, and long-term relationships will remain central to their development and success.